What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?

References

• Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65(11):1869–1873.
   Web of Science ®Google Scholar
• Green D. Pathophysiology of antiphospholipid syndrome. Thromb Haemostasis. 2021 Nov 18. doi:https://doi.org/10.1055/a-1701-2809. Online ahead of print.
   Google Scholar
• Huang S, Ninivaggi M, Chayoua W, et al. VWF, Platelets and the antiphospholipid syndrome. Int J Mol Sci. 2021;22(8):4200.
   PubMedGoogle Scholar
• Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol. 2022;44(3):347–362.
   PubMedGoogle Scholar
• Proulle V, Furie RA, Merrill-Skoloff G, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014;124(4):611–622.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192–200.
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998–1005.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Andreoli L, Limper M, et al., EULAR recommendations for the management of antiphospholipid syndrome inadults. Ann Rheum Dis. 78(10): 1296–1304. 2019.
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Medicine. 1995;332(15):993–997.
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–1138.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848–853.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 20(2): 206–218. 2011.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487–1495.
   PubMed Web of Science ®Google Scholar
• Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009;7(1):15–18.
   PubMed Web of Science ®Google Scholar
• Jackson WG, Oromendia C, Unlu O, et al., Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 1(25): 2320–2324. 2017.
   PubMedGoogle Scholar
• Ohnishi N, Fujieda Y, Hisada R, et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology. 2019;58(6):969–974.
   PubMed Web of Science ®Google Scholar
• Arora S, Nair S, Prabhu R, et al. Role of direct oral anticoagulation agents as thromboprophylaxis in antiphospholipid syndrome. Cureus. 2021;13(10):e19009.
   PubMedGoogle Scholar
• Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426–36.
   PubMed Web of Science ®Google Scholar
• Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials. Autoimmun Rev. 2020;20(1):102711.
   PubMedGoogle Scholar
• Pengo V, Denas G, Zoppellaro G, et al., Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 132(13): 1365–1371. 2018.
   PubMed Web of Science ®Google Scholar
• Woller SC, Stevens SM, Kaplan DA, et al. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin Appl Thrombosis Hemostasis. 2018;24(1):192.
   PubMed Web of Science ®Google Scholar
• Chayoua W, Nicolson PLR, Meijers JCM, et al. Antiprothrombin antibodies induce platelet activation: a possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome? J Thromb Haemost. 2021;19(7):1776–1782.
   PubMedGoogle Scholar
• Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER. Vasc Med. 2016;21(6):506–514.
   PubMedGoogle Scholar
• Ugarte A, de BAG, Ruiz-Arruza I, et al., Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort. Rheumatology. 61(1): 249–257. 2021.
   PubMedGoogle Scholar
• Kravvariti E, Koutsogianni A, Samoli E, et al. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study. Autoimmun Rev. 2020;19(4):102491.
   PubMedGoogle Scholar
• Watanabe T, Oku K, Amengual O, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2017;27(2):225–234.
   PubMedGoogle Scholar
• López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(4):675–682.
   PubMed Web of Science ®Google Scholar
• Canaud G, Bienaimé F, Tabarin F, et al., Inhibition of the mTORC pathway in the antiphospholipid syndrome. New Engl J Medicine. 371(4): 303–312. 2014.
   PubMed Web of Science ®Google Scholar